Trials / Completed
CompletedNCT02856100
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 18 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- Male
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering from PCa. In this study we will image patients with CRPC undergoing second-line anti-androgen therapy (enzalutamide or abiraterone) using 18F-DCFPyL-PET/CT for detection of metastases and therapeutic monitoring, with correlation to standard-of-care conventional imaging modalities (CIM) (CT, bone scan) and clinical follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F DCFPyL- Radiopharmaceutical |
Timeline
- Start date
- 2016-08-03
- Primary completion
- 2019-01-01
- Completion
- 2020-01-01
- First posted
- 2016-08-04
- Last updated
- 2020-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02856100. Inclusion in this directory is not an endorsement.